(Total Views: 527)
Posted On: 03/05/2021 8:51:31 PM
Post# of 151005
Im trying to catch up on all of the posts. Of course this PR came out when I had some very important meetings lined up (not related to this).
Look, this initial data is exciting in that we have a phase 3 trial that proves that Leronlimab reduces mortality by a significant amount. It appears that we missed our Primary Endpoint, but that is not the end of the world.
The trial was too heavily weighted to Severe and not critical. The request to enroll more critical patients will remedy that.
We may still get an EUA in the US and other countries as 24% reduction is FAR and AWAY the best outcome thusfar.
Sure, we all wanted to hit a grand slam, but at a minimum it appears we hit a double. Lets all step back and see what they have to say on the call Monday.
At least now we know that all of these countries have our data and are in the position to make some decisions.
Look, this initial data is exciting in that we have a phase 3 trial that proves that Leronlimab reduces mortality by a significant amount. It appears that we missed our Primary Endpoint, but that is not the end of the world.
The trial was too heavily weighted to Severe and not critical. The request to enroll more critical patients will remedy that.
We may still get an EUA in the US and other countries as 24% reduction is FAR and AWAY the best outcome thusfar.
Sure, we all wanted to hit a grand slam, but at a minimum it appears we hit a double. Lets all step back and see what they have to say on the call Monday.
At least now we know that all of these countries have our data and are in the position to make some decisions.
(8)
(0)Scroll down for more posts ▼
